Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer

Clinical Physiology and Functional Imaging

Volumn 34, Issue 3, 2014, Pages 209-217

  Girard, Danielle ^a   Marino, Frank E ^a   Cannon, Jack ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Lean muscle mass; Muscle quality; Muscle strength; Neuromuscular mechanisms; Normalized peak torque; Peak torque

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT FREE MASS; GRIP STRENGTH; HAND GRIP; HUMAN; KNEE; LEAN BODY WEIGHT; MALE; MUSCLE STRENGTH; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS; THIGH; TORQUE; VERY ELDERLY; BIOMECHANICS; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; SKELETAL MUSCLE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMECHANICAL PHENOMENA; BODY COMPOSITION; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE, SKELETAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TORQUE;

EID: 84898596799     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/cpf.12084     Document Type: Article

References (59)

1. Alibhai SMH, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol (2006); 60: 201-215.
2. Alibhai S, Duong-Hua M, Sutradhar R, Fleshner N, Warde P, Cheung A, Paszat L. Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes. J Clin Oncol (2009); 60: 201-215.
3. Al-Majid S, McCarthy D. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs (2001); 2: 186-197.
4. Aniansson A, Hedberg M, Henning GB, Grimby G. Muscle morphology, enzymatic activity, and muscle strength in elderly men: a follow-up study. Muscle Nerve (2004); 9: 585-591.
5. Arver S, Lehtihet M. Advances in the Management of Testosterone Deficiency. In: Front Horm Res (ed. Jones, TH) (2009); vol. 37, pp. 5-20. Karger Libri AG, Basel, Switzerland.
6. Bandinelli S, Benvenuti E, Del Lungo I, Baccini M, Benvenuti F, Di Iorio A, Ferrucci L. Measuring muscular strength of the lower limbs by hand-held dynamometer: a standard protocol. Aging (1999); 11: 287-293.
7. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (2002); 56: 779-786.
8. Baumgartner R, Waters D, Gallagher D, Morley J, Garry P. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev (1999); 107: 123-136.
9. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De LucaS. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol (2002); 167: 2361-2367.
10. Bhasin S, Woodhouse L, Casaburi R, Singh A, Mac R, Lee M, Yarasheski K, Sinha-Hikim I, Dzekov C, Dzekov J. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab (2005); 90: 678.
11. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002); 360: 103-108.
12. Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male (2005); 3: 207-212.
13. Brawer MK. Hormonal therapy for prostate cancer. Rev Urol (2006); 8: S35-S47.
14. Bylow K, Mohile S, Stadler W, Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? Cancer (2007); 110: 2604-2613.
15. Cannon J, Marino FE. Early-phase neuromuscular adaptations to high-and low-volume resistance training in untrained young and older women. J Sports Sci (2010); 28: 1505-1514.
16. Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet (2004); 363: 978-988.
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences (1988). Lawrence Erlbaum, Hillsdale, NJ.
18. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology (2009); 73: S4-S10.
19. Dutta C. Significance of sarcopenia in the elderly. J Nutr (1997); 127: 992S-993S.
20. Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol (2012); 141: 2.
21. Frontera W, Suh D, Krivickas L, Hughes V, Goldstein R, Roubenoff R. Skeletal muscle fiber quality in older men and women. Am J Physiol Cell Physiol (2000); 279: C611-C618.
22. Gaines JM, Talbot LA. Isokinetic strength testing in research and practice. Biol Res Nurs (1999); 1: 57-64.
23. Galvão D, Spry N, Taaffe D, Newton R, Stanley J, Shannon T, Rowling C, Prince R. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int (2008a); 102: 44-47.
24. Galvão D, Taaffe D, Spry N, Joseph D, Turner D, Newton R. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis (2008b); 12: 198-203.
25. Gilbert SM, Miller DC, Hollenbeck BK, Montie JE, Wei JT. Cancer survivorship-challenges and changing paradigms. J Urol (2008); 179: 431-438.
26. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab (2005); 90: 6410-6417.
27. Greig CA, Botella J, Young A. The quadriceps strength of healthy elderly people remeasured after eight years. Muscle Nerve (2004); 16: 6-10.
28. Gulley J, Aragon-Ching J, Steinberg S, Hussain M, Sartor O, Higano C, Petrylak D, Chatta G, Arlen P, Figg W. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2008); 180: 1432-1437.
29. Hall M, Fritzsch R, Sagalowsky A, Ahrens A, Petty B, Roehrborn C. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology (1999); 53: 898-902.
30. Hansen L, Bangsbo J, Twisk J, Klausen K. Development of muscle strength in relation to training level and testosterone in young male soccer players. J Appl Physiol (1999); 87: 1141-1147.
31. Heymsfield S, Smith R, Aulet M, Bensen B, Lichtman S, Wang J, Pierson R Jr. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr (1990); 52: 214-218.
32. Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R, Singh MAF. Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci (2001); 56: 209-217.
33. Iannuzzi-Sucich M, Prestwood K, Kenny A. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci (2002); 57: 772-777.
34. Joly F, Alibhai S, Galica J, Park A, Yi Q, Wagner L, Tannock I. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol (2006); 176: 2443-2447.
35. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care (2007); 30: 911-917.
36. Klein CS, Rice CL, Marsh GD. Normalized force, activation, and coactivation in the arm muscles of young and old men. J Appl Physiol (2001); 91: 1341-1349.
37. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer (2005); 104: 1633-1637.
38. Levy ME, Perera S, van Londen GJ, Nelson JB, Clay CA, Greenspan SL. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. Urology (2008); 71: 735-739.
39. van Londen G, Levy M, Perera S, Nelson J, Greenspan S. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol (2008); 68: 172-177.
40. Lynch N, Metter E, Lindle R, Fozard J, Tobin J, Roy T, Fleg J, Hurley B. Muscle quality I. Age-associated differences between arm and leg muscle groups. J Appl Physiol (1999); 86: 188-194.
41. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999); 341: 1781-1788.
42. Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol (2006); 175: 1679-1683.
43. Nejat R, Rashid H, Bagiella E, Katz A, Benson M. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol (2000); 164: 1891-1894.
44. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer (2003); 97: 1211-1216.
45. Pierce CA, Block RA, Aguinis H. Cautionary note on reporting eta-squared values from multifactor ANOVA designs. Educ Psychol Meas (2004); 64: 916-924.
46. Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE, McLeod DG. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis (2002); 5: 304-310.
47. Proctor D, Melton IiiL, Khosla S, Crowson C, O'Connor M, Riggs B. Relative influence of physical activity, muscle mass and strength on bone density. Osteoporos Int (2000); 11: 944-952.
48. Salem GJ, Wang M, Young JT, Marion M, Greendale GA. Knee strength and lower-and higher-intensity functional performance in older adults. Med Sci Sports Exerc (2000); 32: 1679-1684.
49. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med (2009); 24: 389-394.
50. Schwartz A, Winters-Stone K. Exercise in Elderly Cancer Survivors. In: Exercise, Energy Balance, and Cancer (eds. Ulrich, CM, Steindorf, K, Berger, NA) (2013); vol. 6, pp. 181-198. Springer, New York, NY.
51. Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM (2009); 102: 625-633.
52. Sealey R, Newman R. A specialized exercise programme for a patient suffering from eosinophilic meningitis. Int J Ther Rehabil (2010); 17: 143-149.
53. Sharifi N, Dahut W, Figg W. Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int (2007); 101: 271-274.
54. Smith M, Finkelstein J, McGovern F, Zietman A, Fallon M, Schoenfeld D, Kantoff P. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002); 87: 599-603.
55. Sowers M, Crutchfield M, Richards K, Wilkin M, Furniss A, Jannausch M, Zhang D, Gross M. Sarcopenia is related to physical functioning and leg strength in middle-aged women. J Gerontol A Biol Sci Med Sci (2005); 60: 486-490.
56. Soyupek F, Soyupek S, Perk H, Özorak A. Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol (2008); 26: 141-146.
57. Spry N, Taaffe D, England P, Judge J, Stephens D, Peddle-McIntyre C, Baker M, Newton R, Galvão D. Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study. Prostate Cancer Prostatic Dis (2012); 16: 66-71.
58. Storer TW, Miciek R, Travison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl (2012) 14: 204-221.
59. Visser M, Fuerst T, Salamone L, Lang T, Harris T. Validity of fan beam dual-energy x-ray absorptiometry for measuring fat-free mass and leg muscle mass. J Appl Physiol (1999); 87: 1513-1520.